Skip to main content
TipRanks
Go Ultimate75% OFF

Spruce Biosciences (SPRB) AI Stock Analysis

483 Followers
SPRB

Spruce Biosciences

(NASDAQ:SPRB)

Select Model
Rating:47Neutral
Price Target:$46.00â–²(6.21% Upside)
Action:reiterated
Date:11/10/26

The score is primarily held back by weak financial performance—persistent losses and significant ongoing cash burn that imply continued reliance on external funding. Technicals are mixed (neutral momentum but still below key longer-term averages), and valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors
Regulatory progressFDA alignment on the planned BLA format and content, together with an intended December submission, marks meaningful progress toward commercialization. If execution remains on schedule, this could move TA-ERT from development into formal regulatory review and clarify its commercial path.
Negative Factors
No recurring product revenueWithout an approved marketed product, Spruce lacks recurring commercial revenue to fund operations and validate its business model. Financial progress therefore remains tied to clinical development, regulatory success, partnering, or future financing rather than established product demand.

Spruce Biosciences (SPRB) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%SPRB-62.34%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$124.47M
Dividend Yield
―
Average Volume (3M)
86.59K
Price to Earnings (P/E)
-1.2
Beta (1Y)
-10.88
Revenue Growth
-100.00%
EPS Growth
58.95%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Spruce Biosciences Business Overview & Revenue Model

Company Description

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions...

How the Company Makes Money

As a clinical-stage biotech, Spruce Biosciences’ ability to generate revenue is typically driven by external financing and, where applicable, collaboration-related payments rather than recurring product sales. Product revenue from commercialized drug...

Spruce Biosciences Financial Statement Overview

Summary

Overall financial quality is weak: revenue is inconsistent and has declined (about $10.1M in 2023 to $4.9M in 2024), profitability is materially negative (TTM net loss about $14.6M; 2024 net loss about $53.0M), and cash burn is heavy with persistently negative operating and free cash flow (TTM OCF about -$51.1M; TTM FCF about -$51.2M). The balance sheet helps (low debt; positive equity around $66.3M TTM), but continued losses and cash outflows create funding/runway risk.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue004.91M10.09M00
Gross Profit004.91M10.09M00
EBITDA-62.54M-38.85M-52.68M-47.37M-45.69M-41.88M
Net Income-67.15M-38.97M-53.04M-47.92M-46.18M-42.29M
Balance Sheet
Total Assets91.95M53.02M45.21M103.95M85.65M126.49M
Cash, Cash Equivalents and Short-Term Investments87.69M48.91M38.75M96.34M79.08M88.97M
Total Debt8.32M736.00K2.77M4.61M6.32M6.53M
Total Liabilities25.65M10.51M16.39M27.44M17.16M15.12M
Stockholders Equity66.30M42.52M28.82M76.51M68.49M111.37M
Cash Flow
Free Cash Flow-51.21M-33.33M-55.96M-33.28M-41.69M-35.97M
Operating Cash Flow-51.07M-33.33M-55.96M-33.27M-41.68M-35.88M
Investing Cash Flow-145.00K0055.78M23.69M-79.17M
Financing Cash Flow128.24M43.48M-1.62M49.14M-241.00K643.00K

Spruce Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price43.31

Price Trends

50DMA47.22Negative
100DMA48.73Negative
200DMA54.06Negative

Market Momentum

MACD-0.31Negative
RSI45.78Neutral
STOCH30.45Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRB, the sentiment is Negative. The current price of 43.31 is below the 20-day moving average (MA) of 44.85, below the 50-day MA of 47.22, and below the 200-day MA of 54.06, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 30.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRB.

Spruce Biosciences Risk Analysis

Spruce Biosciences disclosed 74 risk factors in its most recent earnings report. Spruce Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.*Q3, 2024
2.If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.*Q2, 2024
3.If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.*Q1, 2024

Spruce Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SPRB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FBIOFBIO64Neutral$62.70M0.6574.69%―12.34%―
DTILDTIL54Neutral$211.33M-6.15-58.09%―6353.01%84.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SPRBSPRB47Neutral$124.47M-1.24-118.22%―-100.00%58.95%
CLNNCLNN45Neutral$56.45M-1.63175.40%―11.21%30.44%
IMUXIMUX40Underperform$102.61M-1.68-136.26%――48.29%
IMAIMA39Underperform$43.22M-1.11-32.90%――61.67%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SPRBIMUXFBIOCLNNDTILIMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SPRB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SPRBSpruce Biosciences, Inc.43.31-65.53-60.21%
IMUXImmunic, Inc.7.520.223.01%
FBIOFortress Biotech Inc1.88-0.73-27.97%
CLNNClene Inc3.92-4.69-54.47%
DTILPrecision Biosciences7.572.4347.18%
IMAImagenebio, Inc.3.47-4.23-54.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026